All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.

2023-11-02T16:59:48.000Z

Visual abstract | Autologous stem cell transplantation in newly diagnosed multiple myeloma: Real-world results

Nov 2, 2023
Share:
Learning objective: After reading this article, learners will be able to identify the different regimens used for the transplant sequence in patients with multiple myeloma and their contribution to clinical outcomes.

Bookmark this article

As a first-line therapy, autologous stem cell transplantation (ASCT) remains an important option for patients with multiple myeloma (MM) who are eligible for transplant. With the introduction of novel drugs and advancements in treatments, there are now different approaches taken before and after ASCT, including different combinations of induction, consolidation, and maintenance therapy.

The Multiple Myeloma Hub is pleased to present a visual abstract on a real-world retrospective cohort study by Côté J, et al.1 evaluating the outcomes of ASCT performed as first-line therapy in patients with newly diagnosed MM. The different regimens used for the transplant treatment sequence (induction, consolidation, maintenance) and their contribution to clinical outcomes were evaluated. The study found that:

  • The median overall survival currently exceeds 10 years, except in high-risk patients, with the integration of bortezomib, lenalidomide, and maintenance therapy into the first-line treatment sequence in transplant-eligible patients.
  • Patients who received a second induction regimen had significantly inferior outcomes. However, when maintenance was used, results were comparable regardless of the number of induction regimens administered.
  • Overall, receiving maintenance therapy was significantly associated with better survival outcomes. This advantage was still significant when filtered by those patients who were treated specifically with lenalidomide +/- steroids.
  • In high-risk patients, there was a significant progression-free survival benefit for tandem ASCT, but median overall survival was better with a single ASCT. The benefit of a tandem over single ASCT was not statistically significant when maintenance was given.
  • High-risk patients who received maintenance therapy showed longer median progression-free survival and overall survival regardless of number of induction regimens.
  • None of the analyzed treatment strategies overcame the negative impact of high-risk cytogenetics over survival outcomes, so further research is needed to find an optimized therapeutic approach for these patients.  



 

Visual Abstract

To download this visual abstract, click below.

Download here

  1. Côté J, LeBlanc R, Mian H, et al. Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database. Blood Cancer J. 2023; 13(137). DOI: https://doi.org/10.1038/s41408-023-00905-8

Your opinion matters

HCPs, what is your preferred format for educational content on the Multiple Myeloma Hub?
57 votes - 3 days left ...

Related articles

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox